Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Wardley AM, Pivot X, Morales-Vasquez F, Zetina LM, de Fátima Dias Gaui M, Reyes DO, Jassem J, Barton C, Button P, Hersberger V, Torres AA. Wardley AM, et al. Among authors: button p. J Clin Oncol. 2010 Feb 20;28(6):976-83. doi: 10.1200/JCO.2008.21.6531. Epub 2009 Dec 28. J Clin Oncol. 2010. PMID: 20038734 Clinical Trial.
Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC.
Michael M, White SC, Abdi E, Nott L, Clingan P, Zimet A, Button P, Gregory D, Solomon B, Dobrovic A, Do H, Clarke S. Michael M, et al. Among authors: button p. Asia Pac J Clin Oncol. 2015 Mar;11(1):4-14. doi: 10.1111/ajco.12178. Epub 2014 Feb 27. Asia Pac J Clin Oncol. 2015. PMID: 24575793 Clinical Trial.
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH; CLASSIC trial investigators. Bang YJ, et al. Among authors: button p. Lancet. 2012 Jan 28;379(9813):315-21. doi: 10.1016/S0140-6736(11)61873-4. Epub 2012 Jan 7. Lancet. 2012. PMID: 22226517 Clinical Trial.
First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.
Park K, Yu CJ, Kim SW, Lin MC, Sriuranpong V, Tsai CM, Lee JS, Kang JH, Chan KC, Perez-Moreno P, Button P, Ahn MJ, Mok T. Park K, et al. Among authors: button p. JAMA Oncol. 2016 Mar;2(3):305-12. doi: 10.1001/jamaoncol.2015.4921. JAMA Oncol. 2016. PMID: 26720423 Clinical Trial.
Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies.
Wu YL, Lee V, Liam CK, Lu S, Park K, Srimuninnimit V, Wang J, Zhou C, Appius A, Button P, Hooper G, Palma JF, Schulze K, Scudder S, Shames DS, Yin AY, Zhang G, Mok T; ENSURE FASTACT-2 and ASPIRATION Investigators. Wu YL, et al. Among authors: button p. Lung Cancer. 2018 Dec;126:1-8. doi: 10.1016/j.lungcan.2018.10.004. Epub 2018 Oct 9. Lung Cancer. 2018. PMID: 30527172
SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3.
Pang JB, Castles B, Byrne DJ, Button P, Hendry S, Lakhani SR, Sivasubramaniam V, Cooper WA, Armes J, Millar EKA, Raymond W, Roberts-Thomson S, Kumar B, Burr M, Selinger C, Harvey K, Chan C, Beith J, Clouston D, O'Toole SA, Fox SB; kConFab. Pang JB, et al. Among authors: button p. Am J Surg Pathol. 2021 Aug 1;45(8):1108-1117. doi: 10.1097/PAS.0000000000001701. Am J Surg Pathol. 2021. PMID: 34232604 Free PMC article.
48 results